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We wish to respond to the points raised by Jauhar and colleagues in their Personal View 
published online on 4 February 2016.1 We will outline how the NICE guideline on bipolar 
disorder2 was developed, following the process established by the National Institute for 
Health and Care Excellence (NICE). Notably, this process differs from the development of a 
Cochrane meta-analysis and, indeed, many other guidelines. We then address six specific 
points raised by Jauhar and colleagues.1 
 
The scope for the NICE guideline on bipolar disorder was developed by the National 
Collaborating Centre for Mental Health (NCCMH) and NICE with stakeholders drawn from a 
multidisciplinary group of clinicians from mental health, primary and social care, service 
users and carers, and members of professional and voluntary sector organisations. In this and 
almost all NICE guidelines, the scope was not confined to a single outcome; instead, 
stakeholders identified a range of outcomes in relation to symptoms, relapses, function, 
quality of life, and cost effectiveness. The NCCMH then worked with a Guideline 
Development Group (GDG) to define the review questions covering all areas specified in the 
scope, which included questions about treatment effects as well as questions that typically 
cannot be answered by synthesising randomised controlled trials (RCTs), for example about 
diagnosis and side effects. The GDG comprised practitioners and researchers from varied 
backgrounds, including secondary mental health care, primary care and social care, as well as 
service users and carers.  
 
In line with the NICE guidelines manual,3 it is the responsibility of the GDG chair, the 
guideline facilitator, the NCCMH technical team, the NICE technical support unit, the 
stakeholders (both during scope and guideline consultation), the NICE Commissioning 
Manager and the NICE Guidance Executive to monitor and eliminate allegiance (and any 
other) bias from any interested parties.  All members declared relevant conflicts of interest or 
stated that they had none; these declarations were updated at every meeting and they are 
included in the published guideline. Each member of the GDG agreed to comment on 
evidence using their own expertise, and they agreed not to represent any outside organisation. 
 
The GDG met regularly over an 18-month period. They developed recommendations that 
were informed by systematic reviews of the evidence, including meta-analyses of RCTs and 
syntheses of other studies where appropriate (documented in the full guideline2), as well as 
their own personal and professional expertise, and their values and preferences. Initial 
meetings of the GDG considered issues such as inclusion and exclusion criteria for studies. In 
later meetings, the GDG interpreted evidence presented by the review team. Further checks 
on the process included (i) observation of every meeting by NICE to ensure consistency 
across all NICE guidelines, (ii) peer review and challenge by pre-registered stakeholders, (iii) 
national and international peer review, and (iv) a quality assurance review conducted by 
methodology and subject experts convened by NICE. Minutes of every GDG meeting were 
taken, and reasons for why certain decisions were made were recorded in the full guideline 
(in the ‘From evidence to recommendations’ sections2). Evidence consulted by the GDG is 
fully documented in the guideline, and readers who want to see the review protocols, 
statistical code, meta-analyses (including the data as we entered them), study characteristics, 
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risk of bias assessments, GRADE profiles, etc., can find the full guideline, including 36 
appendices, on the NCCMH website (http://www.nccmh.org.uk/ab_CG_BD_Up.html).  
 
The NICE guideline on bipolar disorder was written to reflect a recovery-orientated approach 
as was indicated by the NICE guideline on service user experience.4 The recommendations 
provide a starting point to guide clinicians in making decisions collaboratively with service 
users and carers. The GDG was aware that NICE guidelines have an important influence on 
the availability of resources and future research. Consequently, it aims to inform decisions 
about current services, and to identify pressing questions for improving the treatment of 
bipolar disorder. It acknowledges uncertainty and heterogeneity in treatment effects, and it 
suggests that choices should be made based on the best available evidence regarding safety, 
effectiveness, and cost, as well as service user, carer, and stakeholder preferences. 
 
After reviewing the evidence, the GDG’s expert assessment was that there is some evidence 
of benefit for both psychological and pharmacological interventions, and although there are 
important limitations in the evidence for both types of treatment, service users (and their 
families and carers) who want access to these services should be able to access them. 
Recommending psychological interventions does not favour one modality, and it does not 
imply that psychological should replace pharmacological interventions; they are not mutually 
exclusive. The guideline recommends that all people with suspected bipolar disorder should 
be assessed in secondary mental health care and that pharmacological treatment should be 
initiated there. In England, psychological interventions for bipolar disorder are available in 
primary or secondary care depending on locality. Therefore, the NICE guideline on bipolar 
disorder reflects the organisation of National Health Service (NHS) care in England, and the 
NICE quality standard for bipolar disorder5 recognises that psychological interventions are 
not currently universally available.  
 
Jauhar and colleagues state that they contacted NCCMH and received no response. None of 
the Guideline Development Group was contacted directly and we can only assume that 
Jauhar and colleagues attempted to make contact via the NCCMH website. The authors of the 
guideline would have been happy to explain the guideline development process, and to 
correct several misunderstandings, if Jauhar and colleagues had contacted us directly. Instead, 
we take six specific points raised by Jauhar and colleagues1 and address them in turn here:  
 
1. We did not ‘correct for multiple comparisons’ 
 
The NICE guideline on bipolar disorder includes many meta-analyses because multiple 
interventions have been evaluated for treating acute episodes (mania and depression) and for 
preventing future episodes; these interventions have been compared with multiple other 
interventions for multiple outcomes at multiple time points. Jauhar and colleagues point to 
these difficulties in evaluating psychological interventions, but evaluations of 
pharmacological interventions are similarly complicated. They do not suggest a way to 
reduce the number of comparisons, and their proposal to correct for multiple comparisons 
would, as Schultz and Grimes state in their 2005 Review on multiplicity in randomized trials, 
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“sabotage interpretation”; the proposed Bonferroni correction would have been inappropriate 
because endpoints were related and not independent in the reviews of both psychological and 
pharmacological interventions.6  
 
In the context of guideline development, reducing the number of outcomes would not have 
addressed the concerns raised during the scoping phase of the development of the guideline 
by stakeholders, who favoured a recovery-based approach to care that considered all aspects 
of care including symptoms, function, acceptability, adverse effects, and quality of life. 
Including these outcomes (and related meta-analyses) was necessary to respond to the scope. 
 
2. We pooled data on different types of psychological interventions 
 
Where there are many available interventions and comparators, pooling them is one way to 
reduce the number of comparisons in a systematic review. Jauhar and colleagues1 appear to 
be undecided about the best way to conduct a review in this complex area (that is, by pooling 
interventions or reporting all comparisons as they were originally described). Like others,7 
the GDG concluded that empirically evaluated psychological treatments were broadly similar 
in content, and therefore made recommendations according to the form of delivery 
(individual, family and group) and indication (acute and long-term treatment).  
 
3. We recommended CBT and psychoeducation for bipolar depression, but the 
evidence does not support this 
 
Overall, the meta-analyses undertaken for the NICE guideline on bipolar disorder found 
evidence that individual acute treatment improved acute depression symptoms, and the 
guideline describes limitations in the quality of the evidence.2 What’s more, a purpose of 
psychological therapies and psychoeducation is to help service users (and their families and 
carers) understand what to expect with bipolar disorder and how they can cope with it. The 
GDG also noted that bipolar depression is so similar to unipolar depression that the disorder 
is often misdiagnosed for many years. Given the purpose of psychological therapies, and 
given robust evidence of the effectiveness of CBT and other psychological treatment 
approaches for unipolar depression, the GDG decided to recommend a choice of individual 
high-intensity or bipolar-specific psychological treatment for the acute management of 
depression symptoms. 
 
4. We excluded a large trial from one analysis 
 
It was decided at an early GDG meeting to consider RCTs for long-term pharmacological or 
psychological treatment. For long-term management, the GDG decided to consider trials with 
a duration of at least 12 months in which participants were euthymic at baseline (see the 
protocol for psychological interventions in the full guideline, p. 2512), and the GDG 
separately considered outcome in trials including people who were acutely depressed or 
acutely manic. That is, the GDG distinguished between pharmacological and psychological 
interventions for (i) the treatment of acute episodes, and (ii) long-term management. 
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Scott and colleagues8 included a mix of participants who were euthymic and participants who 
were depressed. The published report did not distinguish (i) relapse for participants who were 
euthymic from (ii) effects for participants who were depressed. The GDG wrote to Professor 
Scott who was the chief investigator of this publicly funded RCT asking for more detail. 
Professor Scott declined to provide any more data at that time as she felt this “may jeopardise 
future publications”. The meta-analysis shown by Jauhar and colleagues1 should be 
interpreted with caution because only 171 participants were in remission at the time of 
randomisation;8 the real treatment effect may differ depending on what phase participants 
were in when they began the study, and it is unclear how many people who were really “at 
risk” of this outcome experienced it. Including the study, Jauhar and colleagues1 find a non-
significant result, which is not evidence of “no effect” or a “negative result” as they 
incorrectly claim. The published guideline also included results for different types of relapse 
(manic and depressive); additional analyses are included in Appendix 25,2 which reports the 
published data about specific types of relapse at different times. 
 
Although not included in the particular meta-analysis cited by Jauhar and colleagues,1 the 
GDG was aware of this study, discussed its implications, and considered the overall quality 
of the evidence in making their recommendations.  
 
5. We recommended psychoeducation for relapse prevention, but the evidence 
does not support this 
 
Meta-analyses of RCTs are a component of evidence-based practice, and meta-analyses were 
one source of information used by the GDG. Members of the GDG also concluded, based on 
other evidence and based on their own experience and expertise, that psychological 
interventions serve purposes not captured in meta-analyses of RCTs, including providing 
information and support to people in need. The GDG was aware of methodological 
limitations in the available meta-analyses, and they were aware that the evidence was not all 
positive. They considered those limitations and inconsistencies, and they drew appropriately 
circumscribed conclusions. For example, no specific form of therapy emerged as a “gold 
standard”, so the GDG decided to make general rather than specific recommendations about 
treatment strategies. Just as recommendations for pharmacological interventions may change 
if new interventions are developed or new evidence emerges about existing interventions, 
more specific recommendations about psychological interventions may be possible in future 
guidelines if there is more empirical evidence available for psychological interventions. 
 
6. The guideline ignored limitations in the quality of the evidence for 
psychological interventions. 
 
Like the evidence for pharmacological interventions for bipolar depression and long-term 
management, studies of psychological interventions made different comparisons and, in many 
cases, could not be combined for analysis. Most of the evidence for psychological 
interventions came from small studies, and the resulting analyses were limited in quality, so 
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the guideline states that most evidence was low or very low quality.2 The GDG 
acknowledged uncertainty throughout the guideline and concluded that “[psychological 
interventions] might improve symptoms and reduce the risk of relapse and hospital 
admissions”, noting that the “evidence varies in quality”.2 The GDG also made 
recommendations to improve the overall quality of research in this area, and they 
recommended research that could substantially inform, and possibly change, 
recommendations in future versions of guideline. 
 
The guidelines applied the same criteria for pharmacological and psychological interventions 
for bipolar disorder, and the GDG evaluated the strengths and limitations of evidence for both 
approaches. The GDG made recommendations to improve clinical practice on the basis of the 
best evidence that we could obtain at the time. Critics might argue that GDGs should make 
recommendations based only on high-quality evidence, in which case there would be few 
recommendations for either the pharmacological or psychological treatment of severe mental 
illness. It is the opinion of the GDG, stakeholders, peer reviewers and NICE that this would 
have been an unreasonable approach. We certainly hope that subsequent versions of this 
guideline will be served by a more substantial and higher quality evidence base for all 
interventions. 
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